Regeneron Pharmaceuticals reports $3.61 billion revenue for quarter ended March 31, 2026, up 19%
Regeneron Pharmaceuticals reported revenue of $3.61 billion for the quarter ended March 31, 2026, an increase of 19% from the same quarter a year earlier ($3.03 billion).
For the same period it posted net income of $727.2 million, down 10.1%, or $6.75 per diluted share (7.27 a year earlier).
That is a net margin of 20.2%.
On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).
Is Regeneron Pharmaceuticals halal?
See the full AAOIFI screening of Regeneron Pharmaceuticals
See the full AAOIFI screening of Regeneron Pharmaceuticals
Source: 10-Q filed with the U.S. Securities and Exchange Commission on April 29, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.